Graphene-based implant that records brain activity at low frequencies may change our understanding of the brain

Researchers from ICN2, IMB-CNM, CSIC, IDIBAPS, and ICFO have designed a graphene-based implant able to record electrical activity in the brain at extremely low frequencies and over large areas.

Graphene-based implant that records brain activity at low frequencies may change our understanding of the brain image

The team explains that electrode arrays currently used to record the brain’s electrical activity are only able to detect activity over a certain frequency threshold. The new graphene-based technology presented in this work overcomes this technical limitation, allowing access to information found below 0.1 Hz, while at the same time paving the way for future brain-computer interfaces.

NYU team's findings on defects in graphene to benefit environmental and medical sensors

A team of NYU researchers has tackled the longstanding question of how to build ultra-sensitive, ultra-small electrochemical sensors with homogeneous and predictable properties, by discovering how to engineer graphene structure on an atomic level. The team's findings could benefit biochemical detection, environmental monitoring, and lab-on-a-chip applications

Finely tuned electrochemical sensors (also referred to as electrodes) that are as small as biological cells have tremendous potential for medical diagnostics and environmental monitoring systems. However, efforts to develop them have encountered obstacles, like the lack of quantitative principles to guide the precise engineering of the electrode sensitivity to biochemical molecules.

Nanomedical Diagnostics reporting major growth

Nanomedical Diagnostics, a U.S-based producer of graphene biosensors for pharmaceutical and biotherapeutics research, has announced a headquarters relocation, effectively tripling its space from 5,200 to 16,500 square feet.

Nanomedical Diagnostics Agile R100 photo

“This past year has seen exponential growth, both domestically and internationally, for the sales of our drug discovery platforms. We’re in the great position of having to move to a new space to accommodate expanded production and R&D,” says Nanomedical Diagnostics CEO, Ross Bundy. “Our new building enables better operational efficiencies for our production lines and brings departments that were formerly separated in different locations together under one roof. This allows for better collaboration and innovation as we launch new products and grow our staff.”

Zenyatta provides updates on fund-raising and graphene applications progress

Zenyatta logoZenyatta Ventures has announced its plans to raise up to $3,000,000 CAD (around $2,240,000 USD) on a non-brokered private placement basis. The proceeds will be used for bulk sampling, environmental assessment and community engagement.

Zentayya also provided an update on its graphene market development work ,which has led to the creation of five significant potential market verticals for the Company which include aerospace, biomedical, water treatment, transportation and civil engineering.

Graphene to enable ALS diagnosis

A team of researchers from the University of Illinois at Chicago has been working on a way to facilitate ALS diagnosis by using a thin sheet of graphene. This material produces constant vibrations, also known as phonons, whose characteristics change once other materials are placed on its surface. By measuring these changes, researchers are able to tell the differences in the composition of different materials.

“Graphene is just one atom thick, so a molecule on its surface in comparison is enormous and can produce a specific change in graphene’s phonon energy, which we can measure,” Vikas Berry, associate professor and head of chemical engineering in the UIC College of Engineering and an author of the paper, said in a news release.

XFNANO: Graphene and graphene-like materials since 2009 XFNANO: Graphene and graphene-like materials since 2009